Contraceptive devices: subcutaneous delivery systems

Ever since natural sex hormones have been identified, their structure defined and their synthesis achieved, it became clear that their circulating half-life was too short to allow use in therapy. One of the modalities most thoroughly investigated to prolong their duration of action is to embed them in a polymeric matrix and administer them subcutaneously. Research and development activities of devices to be inserted under the skin have focused upon two modalities: the first utilizes the so-called nonbiodegradable devices, in which the matrix is fixed and the drug is made available through diffusion. In the second, biodegradable devices, the matrix dissolves during the process and both the active compound and the matrix components reach the circulation. Although a number of biodegradable systems have been investigated in the form of polymeric rod or micropellets, so far no system has reached the marketplace. Several matrices have been evaluated: poly(ortho esters), (polylactic-polyglycolic acid)co-polymers, poly-(ε-caprolactone). In the case of nonbiodegradable systems, several have been in widespread use for years. The first such system, Norplant® 1, consists of six capsules delivering levonorgestrel and lasts a minimum of 5 years; the second, called Norplant 2 (Jadelle®), consists of only two rods delivering the same amount of steroid of the first system, for the same duration of time. A third system already on the market is made up of a single rod releasing etonogestrel, the active metabolite of desogestrel, with duration of action of 3 years. Additional systems are still at the premarket stage. Subcutaneous implants have several obvious advantages, first and foremost their duration of action that can extend to at least 5 years, making them especially suitable for family-planning programs in developing countries; in addition, they are user- independent, again a positive feature in certain settings. Among the disadvantages, is a relatively complex insertion procedure that, for older systems, required ad hoc trained personnel and a small incision, clearly a disincentive. Newer devices, however, require a much simpler insertion procedure. Extracting systems is also complex and if a woman is lost to follow-up, implants will remain in the subcutaneous tissue forever.

[1]  E. Coutinho,et al.  Use of a single implant of elcometrine (ST-1435), a nonorally active progestin, as a long acting contraceptive for postpartum nursing women. , 1999, Contraception.

[2]  H. Croxatto,et al.  Clinical chemistry in women treated with levonorgestrel implants (Norplant) or a TCu 200 IUD. , 1983, Contraception.

[3]  F. Kincl,et al.  Sustained release hormonal preparations. 1. Diffusion of various steroids through polymer membranes. , 1968, Steroids.

[4]  A. Biswas,et al.  Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids--a randomized comparative study. , 2003, Contraception.

[5]  D. Wise,et al.  An injectable sustained release fertility control system. , 1976, Contraception.

[6]  E R Garrett,et al.  Evaluation, control, and prediction of drug diffusion through polymeric membranes. II. Diffusion of aminophenones through silastic membranes: a test of the pH-partition hypothesis. , 1968, Journal of pharmaceutical sciences.

[7]  I. Fraser,et al.  Norplant consensus statement and background review. , 1998, Contraception.

[8]  S. Monroe,et al.  Clinical evaluation of the Capronor contraceptive implant: preliminary report. , 1989, American journal of obstetrics and gynecology.

[9]  P. Dziuk,et al.  Passage of steroids through silicone rubber. , 1966, Endocrinology.

[10]  D. Mishell,et al.  First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants. , 1997, Contraception.

[11]  E. Diczfalusy,et al.  Hormonal effects of the 300 μg norethisterone (NET) minipill , 1979 .

[12]  D. Mishell,et al.  Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. , 1997, Contraception.

[13]  E. Diczfalusy,et al.  Hormonal effects of the 300 microgram norethisterone (NET) minipill. 3. Comparison of the short-term (2nd month) and medium-term (6th month) effects in 21 subjects. , 1981, Contraception.

[14]  H. Nash,et al.  Release of contraceptive steroids from sustained release dosage forms and resulting plasma levels. , 1978, Contraception.

[15]  L. Bahamondes,et al.  Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women. , 2004, Contraception.

[16]  A. Faúndes,et al.  Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of Norplant implants. , 1985, Contraception.

[17]  G. Benagiano,et al.  Studies on sustained contraceptive effects with subcutaneous polydimethylsiloxane implants. 1. Diffusion of megestrol acetate in humans. , 1973, Acta endocrinologica.

[18]  E. Coutinho Clinical experience with implant contraception. , 1978, Contraception.

[19]  P. Ebden,et al.  Ectopic pregnancy with Implanon® , 2006, Journal of Family Planning and Reproductive Health Care.

[20]  I. Sivin,et al.  Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. International Collaborative Post-Marking Surveillance. , 2001 .

[21]  R. Sitruk-Ware,et al.  Nestorone®: clinical applications for contraception and HRT , 2003, Steroids.

[22]  D. Katz,et al.  Timing of onset of contraceptive effectiveness in Norplant implant users. Part I. Changes in cervical mucus. , 1998, Fertility and sterility.

[23]  E. Diczfalusy,et al.  Facts about an implantable contraceptive: memorandum from a WHO meeting. , 1985, Bulletin of the World Health Organization.

[24]  P. Morales,et al.  Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro. , 1987, Contraception.

[25]  H. Croxatto,et al.  Fertility control in women with a progestogen released in microquantities from subcutaneous capsules. , 1969, American journal of obstetrics and gynecology.

[26]  J. Weikel,et al.  Problems in evaluating chronic toxicity of contraceptive steroids in dogs. , 1977, Journal of toxicology and environmental health.

[27]  K. Barnhart,et al.  Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). , 1997, Human reproduction.

[28]  D. Lewis,et al.  Poly(DL-lactide-co-glycolide)/norethisterone microcapsules: an injectable biodegradable contraceptive. , 1983, Biology of reproduction.

[29]  H. C. Coelingh Bennink,et al.  A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. , 1999, Human reproduction.

[30]  K. Fotherby Potency and pharmacokinetics of gestagens. , 1990, Contraception.

[31]  H. Croxatto,et al.  Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. , 2001, Contraception.

[32]  B. Affandi An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon. , 1998, Contraception.

[33]  H. Croxatto,et al.  Estradiol plasma levels during long-term treatment with Norplant subdermal implants. , 1988, Contraception.

[34]  A. Meli,et al.  MECHANISM BY WHICH 3-ENOL ETHERIFICATION ENHANCES THE ORAL ACTIVITY OF METHYLTESTOSTERONE IN RATS. , 1964, Endocrinology.

[35]  S. Segal The development of NORPLANT implants. , 1983, Studies in family planning.

[36]  J. C. Stucki,et al.  6α-Methyl-17α-HYDROXYPROGESTERONE 17-ACYLATES; A NEW CLASS OF POTENT PROGESTINS1 , 1958 .

[37]  Mike Grace,et al.  One year on , 1999, British Dental Journal.

[38]  J. Trussell,et al.  Reducing unintended pregnancy in the United States. , 2008, Contraception.

[39]  L. Mascarenhas Insertion and removal of Implanon®: practical considerations , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[40]  G. Benagiano,et al.  Studies on sustained contraceptive effects with subcutaneous polydimethylsiloxane implants. 3. Factors affecting steroid diffusion in vivo and in vitro. , 1973, Acta endocrinologica.

[41]  Horacio B Croxatt Progestin implants for female contraception. , 2002, Contraception.

[42]  S. Taneepanichskul,et al.  Effects of the etonogestrel-releasing contraceptive implant (Implanon on parameters of breastfeeding compared to those of an intrauterine device. , 2000, Contraception.

[43]  D. Wise,et al.  Sustained release hormonal preparations for the delivery of fertility‐regulating agents , 2007 .

[44]  G. Benagiano,et al.  Studies on sustained contraceptive effects with subcutaneous polydimethylsiloxane implants. 2. Maintenance of ovarian function in patients with megestrol acetate implants. , 1973, Acta endocrinologica.

[45]  E. Belsey Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. , 1988, Contraception.

[46]  E. R. Garrett,et al.  Evaluation, control, and prediction of drug diffusion through polymeric membranes. I. Methods and reproducibility of steady-state diffusion studies. , 1968, Journal of pharmaceutical sciences.

[47]  A. Faúndes,et al.  Transition from Norplant to Jadelle in a clinic with extensive experience providing contraceptive implants. , 2006, Contraception.

[48]  P. Singh,et al.  Two-year follow-up of changes in clinical chemistry in Singaporean Norplant acceptors: metabolic changes. , 1989, Contraception.

[49]  I. Sivin,et al.  Safety and Efficacy of Levonorgestrel Implant, Intrauterine Device, and Sterilization , 2001, Obstetrics and gynecology.

[50]  C. G. Pitt,et al.  The effect of a biodegradable contraceptive capsule (Capronor) containing levonorgestrel on gonadotropin, estrogen, and progesterone levels. , 1983, American journal of obstetrics and gynecology.

[51]  D. Mishell,et al.  Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. , 2001, Contraception.

[52]  I. Sivin,et al.  The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. , 1998, Human reproduction.

[53]  Odlind,et al.  NORPLANT: biochemical effects. , 1983 .

[54]  G. W. Anderson,et al.  RACEMIZATION BY THE DICYCLOHEXYLCARBODIIMIDE METHOD OF PEPTIDE SYNTHESIS , 1958 .

[55]  W. Ledger,et al.  Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres: phase II clinical study. , 1989, Fertility and sterility.

[56]  J. Nassim Women's bleeding patterns: ability to recall and predict menstrual events. World Health Organization Task Force on Psychosocial Research in Family, Planning, Special Programme of Research, Development and Research Training in Human Reproduction. , 1991, Studies in family planning.

[57]  Post-marketing surveillance of Norplant contraceptive implants: I. Contraceptive efficacy and reproductive health. , 2001, Contraception.

[58]  D. Mishell,et al.  Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. , 2005, Contraception.

[59]  S. Koide,et al.  Nestorone®: a progestin with a unique pharmacological profile , 2000, Steroids.

[60]  B. Chen,et al.  A multicenter comparative clinical study of sino-levonorgestrel-releasing impants-No. I and No. II with Norplant. , 2004 .

[61]  C. Bardin,et al.  Clinical trial with 3-keto-desogestrel subdermal implants. , 1991, Contraception.

[62]  S. Biswas,et al.  Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests -- a randomized comparative study with Norplant implants. , 2004, Contraception.

[63]  H. Gabelnick,et al.  Biodegradable systems for the sustained release of fertility-regulating agents. , 1979, Journal of steroid biochemistry.

[64]  I. Sivin,et al.  Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant implants as controls. , 1997, Contraception.

[65]  I. Sivin,et al.  Long-term contraception with a single implant of the progestin ST-1435. , 1981, Fertility and sterility.

[66]  H. Croxatto,et al.  The pharmacodynamics and efficacy of Implanon. An overview of the data. , 1998, Contraception.

[67]  E. Coutinho,et al.  Effects of a single Silastic contraceptive implant containing nomegestrol acetate (Uniplant) on endometrial morphology and ovarian function for 1 year. , 2006, Contraception.

[68]  G. Benagiano,et al.  Sustained release hormonal preparations. 5. Absorption of 6-methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione from polydimethylsiloxane implants in vivo. , 1970, Acta endocrinologica.

[69]  V. Odlind,et al.  Clinical results with subcutaneous implants containing 3-keto desogestrel. , 1990, Contraception.

[70]  V. Odlind,et al.  “Free Levonorgestrel Index” (FLI) is a better parameter than plasma level of levonorgestrel for predicting risk of pregnancy during use of subdermal contraceptive implants releasing levonorgestrel , 1988, Steroids.

[71]  L. Mascarenhas,et al.  A 2-year comparative study of endometrial histology and cervical cytology of contraceptive implant users in Birmingham, UK. , 1998, Human reproduction.

[72]  S. Ratnam,et al.  Implanon contraceptive implants: effects on carbohydrate metabolism. , 2001, Contraception.

[73]  P. Kratochvíl,et al.  Sustained release hormonal preparations. 6. Permeability constant of various steroids. , 1970, Steroids.

[74]  R. Gurny,et al.  Poly(ortho esters) - their development and some recent applications. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[75]  E. Coutinho,et al.  One year contraception with a single subdermal implant containing nomegestrol acetate (Uniplant). , 1993, Contraception.

[76]  I. Sivin,et al.  Jadelle Levonorgestrel Rod Implants: A Summary of Scientific Data and Lessons Learned from Programmatic Experience , 2002 .

[77]  P. Vilja,et al.  Norplant implants: the mechanism of contraceptive action. , 1991, Fertility and sterility.

[78]  Darney Pd,et al.  Sustained-release contraceptives. , 1990 .